Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 59

1.

Correlations between atazanavir C(trough )and hyperbilirubinemia: a case report.

Uglietti A, Novati S, Gulminetti R, Maserati R.

J Med Case Rep. 2009 Dec 1;3:9307. doi: 10.1186/1752-1947-3-9307.

2.

Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.

Moltó J, Santos JR, Valle M, Miranda C, Miranda J, Blanco A, Negredo E, Clotet B.

Ther Drug Monit. 2007 Oct;29(5):648-51.

PMID:
17898658
3.

Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen.

Boffito M, Kurowski M, Kruse G, Hill A, Benzie AA, Nelson MR, Moyle GJ, Gazzard BG, Pozniak AL.

AIDS. 2004 Jun 18;18(9):1291-7.

PMID:
15362661
4.

Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy.

Winston A, Bloch M, Carr A, Amin J, Mallon PW, Ray J, Marriott D, Cooper DA, Emery S.

J Antimicrob Chemother. 2005 Aug;56(2):380-7. Epub 2005 Jul 4.

PMID:
15996972
5.

Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults.

von Hentig N, Dauer B, Haberl A, Klauke S, Lutz T, Staszewski S, Harder S.

Eur J Clin Pharmacol. 2007 Oct;63(10):935-40. Epub 2007 Jul 31.

PMID:
17665183
6.
7.

Clinically significant adverse events from a drug interaction between quetiapine and atazanavir-ritonavir in two patients.

Pollack TM, McCoy C, Stead W.

Pharmacotherapy. 2009 Nov;29(11):1386-91. doi: 10.1592/phco.29.11.1386.

PMID:
19857154
8.

The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors.

von Hentig N, Babacan E, Lennemann T, Knecht G, Carlebach A, Harder S, Staszewski S, Haberl A.

J Antimicrob Chemother. 2008 Sep;62(3):579-82. doi: 10.1093/jac/dkn204. Epub 2008 May 13.

PMID:
18477709
9.

Outcomes of switch to atazanavir-containing combination antiretroviral therapy in HIV-1-infected patients with hyperlipidemia.

Lu CL, Lin YH, Wong WW, Lin HH, Ho MW, Wang NC, Hsieh SM, Sheng WH, Hung CC, Chen MY.

J Microbiol Immunol Infect. 2011 Aug;44(4):258-64. doi: 10.1016/j.jmii.2010.08.003. Epub 2011 Jan 20.

10.

Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection.

Fabbiani M, Di Giambenedetto S, Ragazzoni E, Colafigli M, Prosperi M, Cauda R, Navarra P, De Luca A.

HIV Med. 2010 May;11(5):326-33. doi: 10.1111/j.1468-1293.2009.00785.x. Epub 2010 Dec 9.

11.

Effect of nevirapine on the steady-state trough concentrations of atazanavir in HIV-infected patients receiving atazanavir/ritonavir.

Moltó J, Deig E, Valle M, Maria Llibre J, Miranda C, Cedeño S, Valero S, Negredo E, Clotet B.

Ther Drug Monit. 2010 Feb;32(1):93-6. doi: 10.1097/FTD.0b013e3181cb479f.

PMID:
20040897
12.

Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.

Gatell J, Salmon-Ceron D, Lazzarin A, Van Wijngaerden E, Antunes F, Leen C, Horban A, Wirtz V, Odeshoo L, Van den Dungen M, Gruber C, Ledesma E; SWAN Study Group.

Clin Infect Dis. 2007 Jun 1;44(11):1484-92. Epub 2007 Apr 25.

PMID:
17479947
13.

Pharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in HIV-infected patients.

Mallolas J, Sarasa M, Nomdedeu M, Soriano A, López-Púa Y, Blanco JL, Martínez E, Gatell JM.

HIV Med. 2007 Mar;8(2):131-4.

14.

Atazanavir in pregnancy: impact on neonatal hyperbilirubinemia.

Mandelbrot L, Mazy F, Floch-Tudal C, Meier F, Azria E, Crenn-Hebert C, Treluyer JM, Herinomenzanahary E, Ferreira C, Peytavin G.

Eur J Obstet Gynecol Reprod Biol. 2011 Jul;157(1):18-21. doi: 10.1016/j.ejogrb.2011.02.005. Epub 2011 Apr 13.

PMID:
21492993
15.

[Efficacy of atazanavir in treatment-naive patients].

Moreno S, Hernández B, Dronda F.

Enferm Infecc Microbiol Clin. 2008 Dec;26 Suppl 17:9-13. doi: 10.1016/S0213-005X(08)76614-X. Review. Spanish.

PMID:
20116611
16.

Atazanavir for the treatment of human immunodeficiency virus infection.

Busti AJ, Hall RG, Margolis DM.

Pharmacotherapy. 2004 Dec;24(12):1732-47. Review.

PMID:
15585441
17.

Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice.

Cleijsen RM, van de Ende ME, Kroon FP, Lunel FV, Koopmans PP, Gras L, de Wolf F, Burger DM.

J Antimicrob Chemother. 2007 Oct;60(4):897-900. Epub 2007 Aug 17.

PMID:
17704117
18.

Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the Italian atazanavir expanded access program and MASTER Cohorts.

Torti C, Lapadula G, Antinori A, Quirino T, Maserati R, Castelnuovo F, Maggiolo F, De Luca A, Paraninfo G, Antonucci F, Migliorino G, Lazzarin A, Di Perri G, Rizzardini G, Esposito R, Carosi G.

Infection. 2009 Jun;37(3):244-9. doi: 10.1007/s15010-008-8010-6. Epub 2009 May 26.

PMID:
19471856
19.

Pharmacokinetic properties and tolerability of bevirimat and atazanavir in healthy volunteers: an open-label, parallel-group study.

Martin DE, Galbraith H, Schettler J, Ellis C, Doto J.

Clin Ther. 2008 Oct;30(10):1794-805. doi: 10.1016/j.clinthera.2008.10.006.

PMID:
19014835

Supplemental Content

Support Center